Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - What's Next?

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $47.67, but opened at $44.75. Kymera Therapeutics shares last traded at $46.18, with a volume of 55,106 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on KYMR shares. Wells Fargo & Company increased their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an "equal weight" rating in a report on Monday, August 12th. Leerink Partners reissued an "outperform" rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. Oppenheimer increased their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Friday, September 27th. B. Riley upped their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a "neutral" rating in a research note on Tuesday, July 9th. Finally, Wolfe Research upgraded Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective on the stock in a research note on Monday, August 26th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $49.00.

Kymera Therapeutics Trading Down 3.1 %

The firm has a market cap of $2.85 billion, a P/E ratio of -19.08 and a beta of 2.21. The business has a 50-day moving average of $47.06 and a two-hundred day moving average of $40.57.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. Kymera Therapeutics's quarterly revenue was up 55.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.67) EPS. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -2.85 EPS for the current year.

Insider Buying and Selling

In related news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. Values First Advisors Inc. purchased a new stake in shares of Kymera Therapeutics during the third quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after buying an additional 504 shares in the last quarter. Comerica Bank raised its position in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company's stock worth $134,000 after buying an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in shares of Kymera Therapeutics in the second quarter worth $139,000. Finally, Quest Partners LLC raised its position in shares of Kymera Therapeutics by 1,402.0% in the second quarter. Quest Partners LLC now owns 5,212 shares of the company's stock worth $156,000 after buying an additional 4,865 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.